

January 14, 2025

Nobelpharma Co., Ltd.

**Curbing Shipments of ACENOBEL<sup>®</sup> Sustained Release Tablet 500 mg  
For Distal Myopathy with Rimmed Vacuoles**

Nobelpharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo, Managing Director & CEO: Jin Shiomura) has started restricting shipments of “ACENOBEL<sup>®</sup> Sustained Release Tablet 500 mg” for distal myopathy with rimmed vacuoles. Since the launch of ACENOBEL on December 19, 2024, the demand for this drug has shown signs to largely exceed our expectation with the possibility of facing a risk of insufficient supply. The Company has made the decision to implement shipment control, at this point, as such surging demands may lead to some difficulties in delivering ACENOBEL to all the patients.

We would like to express our deepest apologies to the patients in need of this drug and their families, as well as the healthcare professionals for not being able to secure the stable supply which is the important mission of a pharmaceutical company.

We will make an announcement as soon as the timing of lifting shipment restriction is determined, which will also be posted on the Company website.

The Company is determined to continue contributing to society by providing critical but neglected pharmaceuticals and medical devices.

[Contact for Inquiries]

Noboru Kudo, Head of Communications

Nobelpharma Co., Ltd.

1-17-24, Shinkawa, Chuo-ku, Tokyo 104-0033

Tel: 03-6670-3800